Original article

Ocular administration of acetazolamide microsponges in situ gel formulations

Manar M. Obiedallah, A.M. Abdel-Mageed, Tahani H. Elfaham *

Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, Egypt

Abstract

In the present work, the antiglaucoma drug, acetazolamide, was formulated as microsponges in situ gel for ocular drug delivery aiming an improved therapeutic efficacy and reduction in the systemic side effects of oral acetazolamide. The microsponges were prepared by the quasi emulsion solvent diffusion method and were incorporated into 25% pluronic F-127 in situ gel. Ethyl cellulose polymer in different proportions with drug was used to prepare the microsponges. Different parameters were evaluated to select the best formulation. The formula S2 with drug to polymer ratio (2:1) showed high entrapment efficiency of about 82% and mean particle size of about 10 \( \mu \)m with polydispersity index (PDI) of 0.22, which are suitable characters for ocular delivery. The in situ gels were evaluated for physicochemical properties (pH, gelling capacity, gelation time and rheological properties) and in vivo studies. S2 formulation showed higher therapeutic efficacy compared to free drug in gel. It was non irritant to the rabbit's eye. These results indicated that acetazolamide microsponges in situ gel have potential ability for ophthalmic delivery.

© 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Microsponges are polymeric delivery systems composed of porous microspheres of an inert polymer that can entrap active ingredients and control their release (Jadhav et al., 2013; Vyas et al., 2010). They are tiny sponge like spherical particles that consist of myriad of interconnected voids within a non-collapsible structure with large porous surface. The size of these microsponges can be varied, usually from 5 to 300 \( \mu \)m in diameter (Jadhav et al., 2013; Vyas et al., 2010). Moreover, it may enhance the stability and reduce the side effects of the active ingredients from topical formulation (Amrutiya et al., 2009).

Microsponges are prepared by several methods as emulsion systems and liquid-liquid suspension polymerization methods. Emulsion systems include water in oil in water (w/o/w) emulsion solvent diffusion, oil in oil emulsion solvent diffusion and quasi emulsion solvent diffusion (ESD) method (Srivastava and Pathak, 2012). Quasi emulsion solvent diffusion (ESD) method is the most common emulsion system used with microsponges preparation (Abdelmalak and El-Menshawe, 2012; Çomog˘lu et al., 2003; Jain and Singh, 2011; Jelvehgari et al., 2006).

Acetazolamide, a carbonic anhydrase inhibitor, is still the most effective drug for the treatment of glaucoma for many years (Kaur et al., 2000), also it is used in the treatment of various forms of epilepsy and to prevent or ameliorate the symptoms of acute high altitude sickness (Mora et al., 2013). In addition, acetazolamide is used as an adjuvant in brain imaging for identifying ischemic areas (Camargo, 2001). To obtain the desired lowering in intraocular pressure (IOP), large oral doses of acetazolamide are used, which would cause peripheral inhibition of carbonic anhydrase enzyme that is distributed in almost all body organs. This usually results in several side effects, which are not tolerated by most of the patients and hence they discontinue the therapy (Epstein and Grant, 1977). The most common reported side effects are diuresis, gastrointestinal symptoms including cramping, epigastric burning, nausea, diarrhea and metabolic acidosis (Granero et al., 2008).

Acetazolamide is available in the market as tablets, capsules and no topical ophthalmic formulation existed due to low permeability coefficient of about \( 4.1 \times 10^{-6} \) cm/sec which limits its ocular bioavailability because of the insufficient amount of the drug.
reaching the ciliary body (Morsi et al., 2014). Thus, many attempts were made in order to develop an effective topical acetazolamide formulation. These attempts include: formulation of acetazolamide in aqueous solutions containing cyclodextrins in order to increase the aqueous solubility of the drug (Ammar et al., 1998), preparation of high-water-content soft contact lenses soaked in 2.5% and 5% acetazolamide to improve the drug effect (Friedman et al., 1985), preparation of polymeric acetazolamide suspension (10%) with penetration enhancers (Kaur et al., 2000), formulation of acetazolamide liposomal dispersions (El-Gazayerly and Hakil, 1997; Hathout et al., 2007) and niosomal dispersions (Aggarwal et al., 2004; Guindedi et al., 2005). More recent attempts include: incorporation of acetazolamide in dendritic nano-architectures (Mishra and Jain, 2014a) and nanoemulsion formulations (Morsi et al., 2017) However, all these attempts were not devoid of problems such as poor patient compliance, difficulty of insertion as in contact lenses and the reported tissue irritation due to the high concentrations of the drug (5% and 10%) as well as toxicological problems accompanied by penetration enhancers. In addition, the most critical problem regarding nanoemulsion formulations is the toxicity of its components (Saifullah et al., 2016).

One of the main problems encountered with the ophthalmic drug delivery systems is the rapid and extensive precorneal loss caused by the drainage and the high tear fluid turnover (Morsi et al., 2017). To overcome these problems an increase in the contact time between drug and corneal surface is required. In situ gelating systems are viscous liquids, which undergo a sol to gel transition, when applied to human body, due to change in a physical-chemical parameter such as temperature, pH or ionic strength (Robinson and Mlynek, 1995). In situ gelling systems allow accurate and reproducible administration of drugs unlike the pre-formed gels, and are capable of prolonging the residence time to the mucosal surfaces (Krauland et al., 2003).

The aim of this study was to formulate novel acetazolamide loaded microsponges and formulating them into in situ gel for ocular drug delivery, in order to decrease the systemic side effects of acetazolamide and increase patient compliance.

2. Materials and methods

2.1. Materials

Acetazolamide (AZM) (99.9% purity) was obtained from CID Company, Egypt. Ethyl cellulose (EC) polymer (degree of substitution 2.42 to 2.53, viscosity of a 5% w/w solution in 80:20 toluene: ethanol by weight at 25 °C, approx. 14cP) was obtained from BDH chemicals Ltd Poole England. Poly vinyl alcohol (PVA) (M. W = 72000) was obtained from MP Biomedicals, LLC, France. Pluronics® F-127(PF-127) and dialysis membrane (MWCO 12–14 kDa) were obtained from Sigma Aldrich, St. Louis, MO, USA. Triethyl citrate (TEC) was from Alfa Aesar GmbH & Co KG, Germany. Dichloromethane (DCM), sodium chloride (NaCl) and calcium chloride dihydrate (CaCl2-2H2O) were obtained from El Nasr Pharmaceutical Chemicals Co., Egypt. Sodium hydroxide scales (NaOH) was obtained from ISO-chem Co. Egypt. Sodium bicarbonate (NaHCO3) was from El Gomhouria Co. Egypt.

2.2. Methods

2.2.1. Preparation of acetazolamide loaded microsponges

Microsponges were prepared by the quasi emulsion solvent diffusion method (Aldawsari and Badr-Eldin, 2013). Firstly, the organic (internal) phase was prepared by dissolving EC polymer and TEC in 10 ml of DCM. TEC (1% w/v) was used as a plasticizer. Then, the calculated amount of the drug was added in the polymeric solution and was ultrasonicated for 20 min in an ice bath using probe ultrasonicator (Model CPX 400, Cole-Parmer instruments Vernon Hills, Illinois U.S.A) for homogenous dispersion and particle size reduction of the drug. The polymeric solution was then added drop wise to the aqueous solution previously prepared by dissolving PVA (0.5% w/v) in 100 ml distilled water at 70 °C with stirring until it was completely dissolved, then the whole mixture was stirred using overhead stirrer at 3000 rpm for two hours till complete evaporation of the organic solvent and formation of the microsponges. The mixture was left in a refrigerator for 24 h for complete precipitation of the microsponges, then, the microsponges were filtered, washed with small amount of diluted sodium hydroxide to remove any free drug, washed several times with double distilled water and dried in an oven at 40 °C for 48 h, then kept for further studies.

2.2.2. Optimization of the formulation parameters and the processing

Several factors that influence the characteristics of the microsponges were studied, to obtain their effects on production yield, entrapment efficiency, drug loading and particle size of microsponges formulations.

2.2.2.1. Effect of the drug to polymer ratio.

Different drug to polymer ratio (AZM: EC) ratios (3:1, 2:1, 1:1, 1:2, 1:3 and 1:4) were investigated to prepare the microsponges formulations. In each formulation, the amounts of DCM (10 ml), PVA (0.5%w/v) and distilled water (100 ml) were kept constant. The microsponges formulations were prepared using overhead stirrer at a stirring speed of 3000 rpm for 2 h. The microsponge formulations possessing drug to polymer ratios 3:1, 2:1, 1:1, 1:2, 1:3 and 1:4 and denominated (S1, S2, S3, S4, S5 and S6 respectively) are shown in Table 1.

2.2.2.2. Effect of the volume of the internal phase (DCM).

The effect of the internal phase volume was investigated by using three different volumes of DCM (5, 10 and 20 ml) to choose the optimum one.

2.2.2.3. Effect of the stirring speed and stirring time.

Different stirring speeds (500, 1000, 2000 and 3000 rpm) and times of stirring (0.5, 1, 2, 4 and 8 h) were employed for the selected formulation to choose the optimum speed and time.

2.2.2.4. Effect of the amount of the emulsifying agent (PVA).

Different concentrations of PVA; 0.1%, 0.3%, 0.5%, 0.7% and 1.0% w/v were evaluated to study the effect of the amount of the emulsifying agent (PVA) on the microsponges formulations.

2.2.2.5. Effect of ultrasonication time.

In order to determine the appropriate ultrasonication time, different times (5, 10 and 20 min) were investigated.

2.2.3. Characterization of the microsponges formulations

2.2.3.1. Particle size and size distribution.

A definite dried amount of the prepared microsponges were suspended in water and were sonicated for one minute to prevent aggregation of the microsponges, then, the mean particle size and size distribution were performed for the microsponges formulation using laser scattering particle size distribution analyzer (HORIBA LA-300). Polydispersity index (PDI) was calculated according to the following equation (Iego, 2012):

\[
PDI = \left( \frac{\sigma}{d} \right)^2
\]

where the polydispersity index (PDI) = the square of the (standard deviation (\(\sigma\))/mean particle diameter (d)). The mean PDI obtained by calculating the average of three PDI calculations.
2.2.3.2. Drug loading (DL%) and entrapment efficiency (EE %). Accurately weighed 50 mg of the drug loaded microsponges were crushed in a mortar, then, transferred to a beaker containing 20 ml of 0.1 M NaOH and stirred on a magnetic stirrer for sufficient time to extract and dissolve the drug, then this solution was filtered using 0.45 μm disc filter and the filtrate was diluted to 100 ml with 0.1 M NaOH solution, then 1 ml was withdrawn, completed to 10 ml with the solution of 0.1 M NaOH and was measured spectrophotometrically at 290 nm against a blank solution similarly treated. The amount of the entrapped drug was calculated using the calibration curve of AZM in 0.1 M NaOH.

The drug loading (DL%) and entrapment efficiency (EE %) were calculated using the following equations (Akash et al., 2013):

Drug loading (%) = \( \frac{\text{amount of drug in microsponges}}{\text{amount of microsponges}} \times 100 \)

Entrapment efficiency (%) = \( \frac{\text{actual drug content}}{\text{theoretical drug content}} \times 100 \)

2.2.3.3. Determination of percentage yield. The formed microsponges were washed, dried and then were weighed accurately. The yield of microsponges was determined by comparing the whole weight of the formed microsponges against the combined weight of the polymer and drug components.

\[ \% \text{yield} = \frac{\text{mass of microsponges obtained}}{\text{total mass of drug and polymer used}} \times 100 \]

2.2.3.4. Microsponges surface morphology. The morphology and surface characteristics of the prepared microsponges were studied using the scanning electron microscopy (SEM). One drop of the homogenously suspended microsponges in water was taken and left till complete drying then coated with gold–palladium alloy under vacuum. Coated samples were then examined using SEM.

2.2.3.5. Differential scanning calorimetric (DSC) analysis. Thermal analysis using a DSC apparatus was carried out on AZM, EC polymer, physical mixture of AZM and EC polymer, plain microsponges (microsponges without the drug) and the selected drug-loaded microsponges formulation using a computer-interfaced shimadzu calorimeter (Model DSC-50, Japan). Samples (approximately 4 mg) were accurately weighed and were put in an aluminum pans and sealed. All samples were run at a heating rate of 10 °C/min over a temperature range 25–350 °C and thermograms were obtained.

2.2.4. Development of acetazolamide loaded microsponges in situ gels

PF-127 hydrogel containing AZM loaded microsponges equivalent to 1% w/w of the drug were prepared by the cold method (El-Laithy et al., 2011). Three different concentrations of plain gels (15, 20 and 25% w/v) were prepared and were tested for their gelling capacity. The concentration that had given the best gelling properties was selected as the best and was used for medicated gel formulation. The weighed amount of PF-127 was slowly added to double distilled water with gentle mixing. The mixture was left in refrigerator at 4 °C overnight for complete swelling of the polymer. After the formation of a clear viscous solution, the accurately weighed amount of microsponges was added to the cold solution and were mixed gently with a glass rod. The solution was sonicated for 1 min at 4 °C to form a homogenous gel.

The free drug in gel was also prepared by adding the calculated amount of the drug to a definite volume of double distilled water and then was ultrasonicated for 2–3 min to decrease the size of drug crystals to about 5–10 μm, after that, the calculated amount of PF-127 powder was added to the preformed suspension, mixed gently and left overnight in refrigerator at 4 °C for complete swelling and dissolution of the polymer in water.

2.2.5. Evaluation of the prepared in situ gels containing acetazolamide loaded microsponges

2.2.5.1. Determination of the pH. The pH of the formulations were determined in triplicate using calibrated pH meter. The average reading was recorded.

2.2.5.2. Determination of the gelation time. The gelation time was determined by tube inversion method (Asasutjarit et al., 2011). 2 ml of the prepared gel maintained at 4 °C was placed in a test tube, the test tube was placed in water bath maintained at gelation temperature (35 °C ± 1), the in situ gel was observed for gelation by inverting the test tube at time intervals. The gelation time was determined when there is no flow of the gel upon tube inversion.

2.2.5.3. Determination of the gelling capacity. The gelling capacity was determined by placing a drop of the in situ gel in a test tube containing 2 ml of freshly prepared simulated tear fluid (pH 7.4) equilibrated at 35 ± 1 °C, the time taken for its gelling formation then dissolution of the gel was visually observed and the gelling capacity was evaluated (Qi et al., 2007) as follows:

| (+) | Immediate gelation and remains for few hours |
| (+++) | Immediate stiff gelation which remains for extended period of time |

2.2.5.4. Determination of the rheological behavior of the prepared gels. Viscosity of the prepared gels were determined using a Brookfield Programmable Rheometer (Model RVDV-III U) Brookfield Engineering laboratories, INC, Middleboro, MA, USA. The viscosity was determined at different shear rates from 10 to 50 rpm and then in a descending order (from 50 to 10 rpm) keeping a period of 10 s at each rpm. The samples were equilibrated at 35 ± 1 °C prior to each measurement. The viscometer was fitted with T-F spindle 96 and the viscosity was investigated. All measurements were performed in triplicates.

Table 1
Composition of various microsponges formulations.

| Components | Drug: polymer ratio |
|------------|---------------------|
|            | S1 | S2 | S3 | S4 | S5 | S6 |
| Acetazolamide (mg) | 300 | 200 | 100 | 100 | 100 | 100 |
| Ethyl cellulose (mg) | 100 | 100 | 100 | 200 | 300 | 400 |
| Triethylcitrate (°sw/v) | 1 | 1 | 1 | 1 | 1 | 1 |
| Poly vinyl alcohol (°sw/v) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Water (ml) | 100 | 100 | 100 | 100 | 100 | 100 |
In vitro release of drug from microsponges alone and from acetazolamide loaded microsponges in situ gel formulations. In vitro release test was performed in 50 ml of simulated tear fluid (STF) solution (pH 7.4 at 35 ± 1 °C) at 50 rpm using the dialysis method. STF is composed of sodium bicarbonate (0.2%), calcium chloride dihydrate (0.008%) and sodium chloride (0.67%) (Marques et al., 2011). A semipermeable standard cellophane membrane was stretched over the end of a dialysis tube, an accurate weight of the microsponges alone or 0.5 g of each of the prepared microsponges gels (each corresponding to 5 mg of the drug) were placed on the membrane in the dialysis tube, which was suspended so that the membrane was just below the surface of the buffered dialysis solution, the assembly allowed to shake at 50 rpm at a temperature maintained at 35 ± 1 °C. Samples of 2 ml were withdrawn from the release medium in the beaker at different time intervals (0.08, 0.25, 0.5, 1, 2, 3, 4, 5 and 6 h) and were analyzed spectrophotometrically at 265 nm against a blank similarly treated. The withdrawn samples were replaced by equal volumes of the STF solution at the same temperature to maintain sink conditions. The experiment was conducted independently in triplicate.

Kinetic analysis of the in vitro release data was also done in order to determine the drug release mechanism, in vitro release data was fitted to a zero-order (m0–m = Kt) first order (log m = log m0–Kt/2.303) and Higuchi model (m0–m = Kt1/2) where m is the amount of the drug remaining in the formulation at time t and m0 is the initial amount of the drug in the formulation (Aksungur et al., 2011; Ali et al., 2014; Costa and Lobo, 2001). The regression coefficient values (R2) were calculated for all the models. Korsmeyer–Peppas equation (m = m0–m0 = Kn) was used to study the diffusion mechanism by analyzing the diffusion exponent “n”. If n ≤ 0.45, the release follows fickian mechanism, if 0.5 ≤ n ≤ 0.8, the release follows non fickian mechanism (Varshosaz et al., 2008).

In vivo efficacy studies. Three domestic rabbits (average weight is 2.5 Kg) were used for each treatment in a cross-over experiment. The rabbits were placed in individual cages with access to food and water. They were maintained in a 12-hour light/12-hour dark cycle in a temperature controlled room (20–25 °C). The experimental procedures conform to the ethical principles of the Egyptian Research Institute of ophthalmology, Giza, Egypt on the use of animals (Monem et al., 2000). Only animals without any signs of ocular inflammation or other observable ocular abnormalities were included in the study. All animals received the five topical treatments: blank microsponges in situ gel (empty microsponges without drug) to establish the IOP baseline before treatment, S2 formula in situ gel (S2 ISG), S3 formula in situ gel (S3 ISG), free drug suspension and the free drug in gel. A 4-day washout period was allowed between treatments. The IOP was measured using standardized schiotz tonometer. Before taking the measurements, the rabbits’ eyes were anaesthetized by instilling 1–2 drops of Benoxinate HCl 0.4% (Benox®) eye drops. A single 50 μl drop of the topical formulae loaded with 1% AZM was instilled into the lower cul-de-sac of the right eye. The left eye received no medication and served as a control. The IOP was measured immediately before administration and at time intervals (0.5, 1, 2, 3, 4 and 5 h) after receiving the medication. The IOP was measured three times at each time interval for the dosed eye and control eye and the means of the readings were taken. The readings were converted into intraocular pressure using the 1955 calibration scale for schiotz tonometer. The change in IOP is expressed as the average difference in IOP (ΔIOP) between the dosed and control eye of the same rabbit using equation (Kaur et al., 2000; Mishra and Jain, 2014b)

\[ \Delta IOP = IOP \text{dosed eye} - IOP \text{control eye} \]

Ocular irritation test. The test was conducted according to the modified Draize test (Baeyens et al., 2002). All the glassware used in the experiment were sterilized by heating and all formulations were prepared under sterile conditions. Three domestic rabbits were used in this experiment. One drop (50 μl) of the microsponges in situ gel formulation was instilled into the lower cul-de-sac of the right eye of each rabbit. The untreated contralateral left eye was used as a control. The eyelids were gently held together for about 10 s to avoid the loss of instilled preparations. Each animal was observed for ocular reactions (redness, swelling discharge, conjunctival chemosis, iris and corneal lesions) at 5, 15, 30 min and 1, 2, 3, 6, 9, 12, 24 h post instillation. The following scores were used to evaluate the irritation (Lallemand et al., 2005). A score of 2 or 3 in any category was considered as an indicator of clinically significant irritation.

| Score | Description                      |
|-------|----------------------------------|
| 0     | No redness, no inflammation or excessive tearing |
| 1     | Mild redness with inflammation and slight tearing |
| 2     | Moderate redness with moderate inflammation and excessive tearing |
| 3     | Severe redness with severe inflammation and excessive tearing |

Stability studies. The stability studies for the prepared microsponges formulations without the gel (S1-S6) were performed at room temperature (25 °C) for 6 months and the effect on EE% and the mean particle size were noticed. Particle size and size distribution were measured after 3 and 6 months of storage. Selected S2 in situ gel microsponges formulation and the free drug in gel were stored at 4 °C for 8 weeks and were evaluated for pH and drug content to know the stability of microsponges in gel versus free drug in gel. 0.5 g of gel (theoretical drug content was 5 mg) was taken at each time interval and was dissolved in 0.1 M NaOH for extraction of the drug, filtered and then measured spectrophotometrically at 290 nm to determine the drug content.

Statistical analysis. Statistical analysis was carried out using GraphPad Prism software version 5. One-way analysis of variance (ANOVA) was used to analyze the differences between experimental groups. Newman-Keuls method was used as a post-hoc test. A probability of less than 0.05 (p < 0.05) was considered statistically significant. All experiments were conducted in triplicate and the results were presented as means ± SD.

Results and discussion

Preparation and characterization of microsponges formulations

AZM microsponges were prepared by the quasi emulsion solvent diffusion method using EC polymer which is biologically inert, non-irritating, non-mutagenic, non-allergenic, non-toxic and non-biodegradable polymer (Parikh, 2010). Quasi emulsion solvent diffusion method seems to be easy, reproducible, rapid and has an advantage of avoiding solvent toxicity (Re and Biscans, 1999).

Effect of the formulation parameters on the mean particle size, PDI, EE% and DL%

Effect of the drug to polymer ratio on the production yield, drug content, entrapment efficiency and mean particle size is illustrated in Table 2. The statistical manipulation of the results using GraphPad Prism software version 5, one-way analysis of variance (ANOVA) revealed that the polymer and drug concentration have a great influence on the EE%
The effect of the volume of DCM on microsponges formation (Values are the mean ± SD (n = 3)).

Table 2

| Batch Code | Drug:Polymer ratio | Production yield (%) | Theoretical drug content (%) | Actual drug content (%) | Entrapment efficiency (%) | Mean particle size (µm) | PDI |
|------------|-------------------|----------------------|-----------------------------|-------------------------|---------------------------|------------------------|-----|
| S1         | 3:1               | 58.18 ± 0.47         | 75.00                       | 69.32 ± 3.56           | 92.42 ± 4.7              | 17.00 ± 0.45           | 0.28 ± 0.08 |
| S2         | 2:1               | 42.10 ± 1.56         | 66.67                       | 54.65 ± 1.37           | 82.02 ± 2.5              | 10.89 ± 1.02           | 0.22 ± 0.12 |
| S3         | 1:1               | 31.33 ± 7.85         | 50.00                       | 23.80 ± 1.85           | 47.59 ± 4.5              | 11.10 ± 0.60           | 0.40 ± 0.07 |
| S4         | 1:2               | 47.75 ± 9.55         | 33.33                       | 13.50 ± 2.05           | 40.51 ± 7.5              | 14.03 ± 0.78           | 0.15 ± 0.03 |
| S5         | 1:3               | 25.50 ± 1.77         | 25.00                       | 6.82 ± 2.18            | 27.28 ± 8.7              | 16.99 ± 2.21           | 0.20 ± 0.06 |
| S6         | 1:4               | 29.80 ± 1.98         | 20.00                       | 5.37 ± 1.25            | 26.85 ± 6.2              | 35.30 ± 2.72           | 0.65 ± 0.25 |

The effect of the drug to polymer ratio on microsponges formation (Values are the mean ± SD (n = 3)).

Table 3

| Batch Code | Volume of DCM (ml) | Production yield (%) | Actual drug content (%) | Entrapment efficiency (%) | Mean particle size (µm) | PDI |
|------------|--------------------|----------------------|-------------------------|---------------------------|------------------------|-----|
| S7         | 5                  | 35.32 ± 2.15         | 55.49 ± 2.28            | 83.23 ± 3.42             | 25.61 ± 3.42           | 0.26 ± 0.08 |
| S2         | 10                 | 44.02 ± 3.56         | 54.65 ± 1.37            | 82.02 ± 2.51             | 10.89 ± 2.51           | 0.22 ± 0.12 |
| S8         | 20                 | 25.24 ± 0.37         | 27.50 ± 0.95            | 41.24 ± 1.43             | 11.65 ± 1.43           | 0.22 ± 0.01 |

3.1.1.2. Effect of the volume of the internal phase. The results in Table 3 show that increasing the volume of DCM decreases the mean particle size of the microsponges. The small PDI values observed for all formulations which are suitable for ophthalmic administration.

3.1.1.3. Effect of the stirring speed and stirring time. The stirring speed was found to have the greatest influence on microsponges particles size as shown in Table 4. The mean particle size was found to be significantly decreased (P < 0.05) from (92.42 ± 4.7) to (47.59 ± 4.5) as the drug concentration decreased from S1 to S3 formulae, also, increasing the polymer concentration from (1:1) drug : polymer ratio in S3 formula to (1:4) in S6 formula resulted in decreasing of the EE% from 47.59 ± 4.5 to 26.85 ± 6.2. This result could be attributed to the increasing in viscosity due to increasing the polymer concentration which led to formation of more rigid polymer coat and difficulty of drug transfer with more viscous medium resulted in low EE%. This is in agreement with the opinion of (Nadia Morsi, et al) who interpreted that increasing in polymer concentration resulted in low EE% due to formation of compact polymer coat that hindered the drug entrapment (Morsi et al., 2016). The mean particle size of the microsponges ranged from 10.89 ± 1.02 for S2 formula to 35.30 ± 2.72 for S6 formula. Increasing the polymer concentration was found to significantly increase the particle size (P < 0.05). S3, S5, and S6 formulae were significantly different in particle sizes (P < 0.01). This result may be due to increasing the viscosity of the dispersed phase resulted in formation of large globules which were hard to be divided into smaller particles, hence larger droplets were formed and the mean particle size increased. The small PDI values observed for all formulations which are shown in Table 2 indicated that the microsponges were homogeneous and had narrow size distribution except S6 formulation which had a high PDI value of about 0.65 ± 0.25.

3.1.1.4. Effect of the amount of emulsifying agent (PVA). The effect of the amount of emulsifying agent on microsponges formulations is shown in Table 6. There were no significant differences in EE% by using different concentrations of PVA (P > 0.05), it was observed that as the amount of PVA increased from 0.1 to 0.5% w/v, significant decrease in the mean particle size was observed (P < 0.05), which was in agreement of the opinion of (Vysloužil J, et al) who reported that an excessive increase of PVA concentration (P < 0.05), which was in agreement of the opinion of (Vysloužil J, et al) who reported that an excessive increase of PVA concentration (P < 0.05), which was in agreement of the opinion of (Vysloužil J, et al) who reported that an excessive increase of PVA concentration (P < 0.05), which was in agreement of the opinion of (Vysloužil J, et al) who reported that an excessive increase of PVA concentration (P < 0.05). 30 min stirring time was not enough for formation of microsponges due to incomplete evaporation of DCM. Two hours of stirring time was chosen as appropriate time for formation of microsponges and ensure the complete evaporation of DCM.
particle size suitable for ophthalmic administration are shown in Table 8.

3.1.2. Characterization of microsponges formulations

3.1.2.1. Microsponges surface morphology. Fig. 1 shows the scanning electron micrographs of microsponges formulation S2. The figure clearly demonstrates that the particles are within the size range of 10 µm and that they are hollow with spherical shape and porous surface. Minor drug particles were also adsorbed on the surface of microsponges as shown in Fig. 1B.

3.1.2.2. Differential scanning calorimetric (DSC) analysis. DSC studies were carried out to confirm compatibility between the drug and the polymer. The thermal behavior of the drug, EC polymer, physical mixture of drug & EC polymer, plain formula (pure microsponges without drug) and selected formula S2 are presented in Fig. 2. The thermograms showed a sharp endothermic peak at 260 °C corresponding to the melting point of AZM in the crystalline form. The DSC curves of the physical mixture of drug and polymer and S2 formula exhibited the same characteristic peak of the drug. The results indicate that the drug is intact and preserves the peak of its melting point at 260 °C. Also it is indicative of the compatibility between the drug and the polymer, and the suitability of the preparation process. The small intensity of the endothermic peak in S2 formula compared to the physical mixture indicates the good entrapment of the drug inside the voids of the microsponges. No new peaks were observed in the melting point range as observed in the DSC thermograms of microsponges formulation.

Table 4
The effect of stirring speed on microsponges formation (Values are the mean ± SD (n = 3)).

| Batch Code | Stirring speed (rpm) | Production yield (%) | Actual drug content (%) | Entrapment efficiency (%) | Mean particle size (µm) | PDI |
|------------|----------------------|----------------------|------------------------|--------------------------|------------------------|-----|
| S9         | 500                  | 73.32 ± 3.31         | 63.29 ± 4.23           | 94.96 ± 6.03             | 296.79 ± 0.22          | 0.12 ± 0.02 |
| S10        | 1000                 | 61.77 ± 1.26         | 59.44 ± 0.16           | 88.88 ± 0.2              | 96.96 ± 7.98           | 0.17 ± 0.06 |
| S11        | 2000                 | 51.16 ± 1.17         | 61.05 ± 1.06           | 91.58 ± 1.57             | 34.61 ± 4.18           | 0.12 ± 0.02 |
| S2         | 3000                 | 42.45 ± 3.56         | 54.65 ± 1.37           | 82.02 ± 2.51             | 10.89 ± 1.02           | 0.22 ± 0.12 |

3.1.2.3. In-vitro release of acetazolamide from microsponges without the gel. S1, S2, S3 and S4 formulations were chosen for release studies due to their small particle size and high to moderate EE%. The in vitro release studies of these formulations compared to the release of free drug are shown in Fig. 3. The free drug had shown to exhibit a significant higher and faster release (P < 0.001) than from microsponges formulations. The free drug showed about 67.8% of cumulative release after one hour whereas the microsponges formulations showed 6.36–37.87% drug release after one hour. After 2 h, almost all free drug was released (about 93.38%) from the membrane. EC polymer was found to retard the release of the drug from microsponges to a large extent, also increasing the polymer concentration with respect to drug was found to retard the drug release as shown in S4 formula. This could be attributed to that the microsponges retarded the drug release due to inclusion of the drug within the voids of the microsponges. These voids acted as a drug reservoir and prolonged the release.

Table 5
The effect of stirring time on microsponges formation (Values are the mean ± SD (n = 3)).

| Batch code | Time of stirring (hs) | Production yield (%) | Actual drug content (%) | Entrapment efficiency (%) | Mean particle size (µm) | PDI |
|------------|----------------------|----------------------|------------------------|--------------------------|------------------------|-----|
| S12        | 1                    | 40.68 ± 2.58         | 52.36 ± 2.44           | 78.54 ± 3.66             | 13.04 ± 1.45           |     |
| S2         | 2                    | 42.45 ± 3.32         | 54.65 ± 1.37           | 82.02 ± 2.12             | 10.89 ± 1.02           |     |
| S13        | 4                    | 39.85 ± 3.21         | 53.77 ± 2.91           | 80.65 ± 4.36             | 10.22 ± 1.98           |     |
| S14        | 8                    | 47.97 ± 5.36         | 57.13 ± 2.21           | 85.69 ± 3.32             | 11.21 ± 0.79           |     |

Table 6
The effect of the amount of emulsifying agent on microsponges formation. (Values are the mean ± SD (n = 3)).

| Batch code | Amount of PVA (%w/v) | Production yield (%) | Actual drug content (%) | Entrapment efficiency (%) | Mean particle size (µm) | PDI |
|------------|----------------------|----------------------|------------------------|--------------------------|------------------------|-----|
| S15        | 0.1                  | 37.87 ± 2.87         | 59.71 ± 2.35           | 89.60 ± 3.50             | 22.0 ± 3.21           | 0.71 ± 0.58 |
| S16        | 0.3                  | 90.0 ± 9.30          | 60.03 ± 1.06           | 90.08 ± 1.56             | 17.12 ± 0.25          | 0.31 ± 0.04 |
| S2         | 0.5                  | 42.45 ± 3.56         | 54.65 ± 1.37           | 82.02 ± 2.51             | 10.89 ± 0.72          | 0.22 ± 0.12 |
| S17        | 0.7                  | 48.05 ± 3.32         | 59.15 ± 0.62           | 88.73 ± 0.92             | 17.55 ± 1.32          | 0.25 ± 0.09 |
| S18        | 1                    | 57.83 ± 0.17         | 54.70 ± 3.31           | 82.07 ± 4.95             | 12.44 ± 1.74          | 0.26 ± 0.08 |

Table 7
The effect of the ultrasonication time on microsponges formation (Values are the mean ± SD (n = 3)).

| Batch code | Ultrasonication time (min.) | Production yield (%) | Theoretical drug content (%) | Actual drug content (%) | EE% | Mean particle size (µm) | PDI |
|------------|----------------------------|----------------------|----------------------------|------------------------|-----|------------------------|-----|
| S19        | 5                          | 38.35 ± 1.65         | 66.67                      | 45.77 ± 1.50            | 68.73 ± 2.25 | 19.11 ± 0.13 | 0.28 ± 0.03 |
| S20        | 10                         | 32.16 ± 3.50         | 66.67                      | 48.49 ± 2.02            | 72.82 ± 3.04 | 19.35 ± 0.69 | 0.31 ± 0.05 |
| S2         | 20                         | 42.45 ± 3.56         | 66.67                      | 54.65 ± 1.68            | 82.02 ± 2.51 | 10.89 ± 1.02 | 0.22 ± 0.12 |

Table 8
Optimum parameters for microsponges preparation with quasi-emulsion solvent diffusion method to obtain the size suitable for ophthalmic administration.

| Specification | Optimum value |
|---------------|---------------|
| Drug: polymer ratio | 2:1 |
| Conc of PVA (3%w/v) | 0.5 |
| Volume of organic solvent (ml) | 10 |
| Volume of water in external phase (ml) | 100 |
| Ultrasonication time (minutes) | 20 |
| Stirring speed (rpm) | 3000 |
| Stirring time (hs) | 2 |
Increase the polymer concentration led to increase the wall thickness and the size of the prepared microsponges, resulting in the reduction of surface area and retardation of the drug release from the microsponges. Also, the slow drug release from microsponges may be attributed to the hydrophobic and floating properties of the microsponges leading to reduction of the drug release.

3.2. Evaluation of the prepared gels containing acetazolamide microsponges

3.2.1. Determination of the pH

The ideal pH for an opthalmic preparation should be in the range of 7.2 ± 0.2 (Ammar et al., 2009). The pH values of the prepared gel formulations were measured and found to be in the range of 6.64 to 7.14 (Table 9). However, the limited buffering capacity of the tears is able to adjust the pH values to the physiological pH if it ranged from 3.5 to 8.5 (Fialho and Silva-Cunha, 2004). Therefore the prepared microsponge gels are adequate for ocular application because they were not buffered and could be adjusted to the physiological pH values by tears.

3.2.2. Determination of the gelation time

The ideal in situ gelling system is the system which is gelled rapidly on exposure to body temperature to prevent its quick removal by tear fluid (Venkatesh et al., 2013). S1, S2 and S3 in situ gels formulations (S1 ISG, S2 ISG and S3 ISG respectively) showed quick gelation time of about 22 to 24 s as presented in Table 9. It was noticed that S4 in situ gel (S4 ISG) showed shorter gelation time of about 17 s which may be due to the large amount of microsponges used during preparation because the EE% of S4 formula was low (40.5% only) compared to S2 formula (82%).

![Fig. 1. Scanning electron micrographs of microsponges formulation S2.](image1)

![Fig. 2. DSC thermograms of (1) S2 formula, (2) Physical mixture of drug and EC polymer, (3) Plain formula (EC microsponges without drug), (4) EC polymer, (5) Pure AZM.](image2)
3.2.3. Determination of the gelling capacity

It was observed that (15% w/v PF-127) showed no gelation (“−” grade of gelling capacity) at physiological temperature (35 °C). The (20% w/v PF-127) showed “+” grade of gelling capacity which was formed after few minutes and dissolved rapidly. The (25% w/v PF-127) showed “++” grade of gelling capacity which is reported as the most satisfactory grade (Song et al., 2013), so, this concentration was used for different microsponges gel formulations due to its best gelling capacity characters. The results of the gelling capacity of different microsponges gel formulations are shown in Table 9, it was noticed that all medicated in situ gel formulations were gelled immediately when exposed to STF at 35 ± 1 °C and it retained for about 4 to 5 h.

3.2.4. Determination of the rheological behavior of the prepared gels

The rheological behavior of the in situ gel formulations (S1 ISG-S4 ISG) is cited in Fig. 4. It was found that the formulations exhibited pseudoplastic flow characteristics (shear thinning systems); the viscosity was increased at low shear rates and decreased under conditions of high shear rates. An advantage of shear thinning formulations is that they have a high viscosity in the open eye, stabilizing the tear film. When blinking occurs, such polymers thin, preventing the feeling of irritation that would occur with high viscosity Newtonian fluid (Fiscella, 2008) and thus allow a good distribution of the formulation over the surface of the eye.

3.2.5. In-vitro release of acetazolamide from in-situ gel formulations

Fig. 5 shows the in vitro release profile of AZM from in situ gel formulations S1 ISG to S4 ISG compared to the release of free drug in gel. Incorporation of the medicated microsponges in pluronic gels enhanced the drug release as PF-127 gel decreased the hydrophobic characteristics of the microsponges. This is because PF-127 is non-ionic polymeric surfactant (Schmolka, 1972) which led to increase in the wettability of the microsponges. S1 ISG and S2 ISG formulations showed superior drug release compared to other formulations. S4 ISG formula showed the slowest drug release.

Table 9

| Batch Code | pH measurement | Gellation time (s) | Gelling capacity |
|------------|----------------|-------------------|-----------------|
| S1 ISG     | 7.14 ± 0.11    | 22.33 ± 0.58      | ++              |
| S2 ISG     | 7.01 ± 0.03    | 24.67 ± 2.89      | ++              |
| S3 ISG     | 6.64 ± 0.12    | 23.00 ± 3.61      | ++              |
| S4 ISG     | 6.98 ± 0.01    | 17.00 ± 2.65      | ++              |

Fig. 4. The rheological profile of the medicated in situ gel formulations.

Fig. 3. In vitro release profiles of AZM from S1, S2, S3 and S4 microsponges formulations compared to free drug release.
release due to increasing the concentration of EC polymer which retarded drug release as discussed before in the in-vitro release of AZM from microsponges alone.

3.2.6. Kinetic analysis of the in vitro release data

In order to obtain the mechanism of drug release, the data was fitted according to different release models and the correlation coefficients ($r^2$) were calculated and shown in Table 10. Almost the drug release from the microsponges in situ gels followed Higuchi diffusion model. The diffusion exponent “n” of the Korsmeyer–Peppas equation was $0.5 \leq n \leq 0.8$ which indicated anomalous diffusion or Non-Fickian diffusion mechanism.

3.2.7. In vivo efficacy studies

The results of the in vivo efficacy studies are shown in Fig. 6. The results showed that the free drug suspension showed rapid reduction in the IOP values (about $-4.5$) after half an hour from instilling the drug into the eye and the effect was rapidly depleted.

Table 10

| Batch code | Zero order ($r^2$) | First order ($r^2$) | Higuchi model ($r^2$) | Korsmeyer–Peppas (n) |
|------------|--------------------|---------------------|----------------------|----------------------|
| S1 ISG     | 0.9768             | 0.9968              | 0.9952               | 0.58                 |
| S2 ISG     | 0.9780             | 0.9956              | 0.9973               | 0.69                 |
| S3 ISG     | 0.9800             | 0.9908              | 0.9908               | 0.89                 |
| S4 ISG     | 0.9733             | 0.9835              | 0.9940               | 0.74                 |

Fig. 5. In vitro release profile of AZM from S1 ISG, S2 ISG, S3 ISG and S4 ISG formulations compared to the release of free drug in gel.

Fig. 6. Changes of IOP values with time in the treated normal rabbits for S2 ISG and S3 ISG formulae compared to free drug in gel and drug suspension. (Note that: The negative sign indicates that the IOP values decreased below than the normal level).
within one hour. The rapid and weak effect of the drug suspension was attributed to the rapid washing out of the instilled eye drops and the low permeability coefficient of AZM (4.1 × 10^{-6} cm/ sec). There was significant decrease in the IOP values with S2 and S3 formulae versus plain formula at all measurement times (p < 0.05). The free drug in gel showed significant decrease in the IOP values than plain formula after the first 2 h only (p < 0.01). S2 ISG formula showed significant decrease in the values of IOP after 2 and 3 h compared to free drug in gel (p < 0.05), also S3 ISG formula showed significant decrease in the IOP values after 3 h (p < 0.01) compared to free drug in gel. It was observed that S2 ISG formula exhibited the maximum and fastest decrease in the IOP values (−7.3 after 0.5 h) while S3 ISG formula showed decrease in the IOP values of about (−6.3) compared to free drug in gel (the maximal decrease was −5.5 after 1 h). Although, the in vitro release of free drug in gel was higher, its in vivo therapeutic efficacy was lower than S2 and S3 formula in gel due to the low permeability coefficient of AZM which limits its ocular bioavailability. The instillation of the free drug in gel into rabbit’s eye released the drug rapidly till one hour and affected the IOP, then, the amount of the drug decreased and accordingly, the influence on IOP decreased. On the contrary, in case of formulae S2 and S3, the release of AZM was continued from the microsponges which gave higher ocular permeability (due to inclusion into microsponges which allowed more residence time) and so, the effect on IOP was higher. The effect of S2 ISG and S3 ISG formulations was remained for about 5 h while the effect of the free drug suspension and free drug in gel remained only for 2 and 3 h respectively.

It was found that there were no changes in the values of IOP observed in the untreated eye during the period of treatment indicating that the formulations produced the effect due to a local action not due to the systemic absorption of the drug.

3.2.8. Ocular irritation test

No signs of ocular irritation such as redness, tearing or swelling were observed in S2 ISG formula indicating that it is not irritant. However, S3 ISG formula showed slight redness and tearing which disappeared after 30 min as shown in Fig. 7. It may be due to the high microsponges content during gel preparation because of the low drug EE% in S3 compared to S2 formula.

3.2.9. Stability studies

The results of stability studies of the microsponges without the gel are shown in Table 11. It was observed that there were no significant changes in the EE (%) or the mean particle size of the microsponges (S1-S6) over the whole period of storage. It was concluded that the formulation of microsponges alone were stable for 6 months of storage at room temperature (25°C). Table 12 shows

![Fig. 7. Ocular irritation test of S3 ISG formula after (a) 15 min, (b) 30 min) of the treated right eye compared to (c) left untreated (control) eye.](image)

| Parameters | Formulation code | Sampling time  | Initial | 1 month | 2 months | 3 months | 4 months | 5 months | 6 months |
|------------|------------------|----------------|---------|---------|----------|----------|----------|----------|----------|
| EE (%)     | S1               |                | 92.42 ± 4.7 | 95.82 | 91.65 | 92.58 | 90.33 | 92.82 | 90.88 |
|           | S2               |                | 82.02 ± 2.5 | 82.71 | 84.55 | 82.60 | 83.29 | 81.35 | 82.26 |
|           | S3               |                | 47.59 ± 4.5 | 50.63 | 45.72 | 50.23 | 48.50 | 47.60 | 48.94 |
|           | S4               |                | 40.51 ± 7.5 | 41.84 | 42.26 | 35.82 | 36.22 | 41.39 | 40.48 |
|           | S5               |                | 27.28 ± 8.7 | 26.60 | 21.22 | 26.25 | 30.65 | 27.86 | 27.52 |
|           | S6               |                | 26.85 ± 6.2 | 26.20 | 21.80 | 25.48 | 27.60 | 23.21 | 23.76 |
| Mean particle size (µm) | S1               |                | 17.00 ± 0.45 |         | 17.28 |         |         |         |         |
|           | S2               |                | 10.89 ± 1.02 |         | 11.05 |         |         |         |         |
|           | S3               |                | 11.10 ± 0.60 |         | 12.59 |         |         |         |         |
|           | S4               |                | 14.03 ± 0.78 |         | 13.91 |         |         |         |         |
|           | S5               |                | 16.99 ± 2.21 |         | 15.99 |         |         |         |         |
|           | S6               |                | 35.30 ± 2.72 |         | 35.83 |         |         |         |         |
the results of stability studies of the selected S2 formula in gel (S2 ISG) compared to free drug in gel at 4 °C. It is observed that the drug content (%) for the free drug in gel decreased by about 12.7% and 23.77% after 2 weeks and 8 weeks of storage respectively. The selected S2 ISG showed a decrease in drug content by about 2.9% only and 19.1% after 4 weeks and 8 weeks of storage respectively. It is concluded that the incorporation of the drug into the microsponges increases the stability of the drug in gel till 4 weeks of storage at a temperature of 4 °C. Concerning the pH, it is noticed that there were no any significant changes in the pH values for the two formulations studied over the whole period of storage.

4. Conclusion

Stable acetazolamide microsponges were successfully prepared by the quasi emulsion solvent diffusion method. The microsponges were spherical porous particles as shown by SEM. S2 formula showed a mean particle size of about 10 µm which is suitable for ocular administration. The microsponges were incorporated into (25% w/v) pluronic F-127 in situ gels. The prepared gels exhibited pseudoplastic rheological properties which is more comfortable to the eyes. The in vitro release kinetics of the gel formulations followed Higuchi diffusion model. The optimized S2 formula in gel could significantly decrease the IOP in rabbits’ eyes causing no irritation. Acetazolamide microsponges in situ gel formulations could be successfully used for topical ocular administration for the treatment of glaucoma and avoiding the systemic side effects accompanied by oral acetazolamide.

References

Abdelmalak, N.S., El-Menshawe, S.F., 2012. A new topical fluconazole microsphere loaded hydrogel: preparation and characterization. Int. J. Pharm. Pharm. Sci. 4 (1), 460–469.
Aggarwal, D., Garg, A., Kaur, I.P., 2004. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J. Pharm. Pharmacol. 56 (12), 1509–1517.
Akhsh, M., Iqbal, F., Raza, M., Rehman, K., Ahmed, S., 2013. Characterization of ethylcellulose and hydroxypropyl methylcellulose microspheres for controlled release of Flurbiprofen. J. Pharm. Drug Deliv. Res. 2 (1), 2.
Asksungur, P., Demirbilek, M., Denkbas, E.B., Vandervoort, J., Ludwig, A., Unlu, N., 2011. Development and characterization of Cyclosporin A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J. Controlled Release 151 (3), 286–294.
Aldawarsi, H., Badi-Eldin, S.M., 2013. Microsponges as promising vehicle for drug delivery and targeting: preparation, characterization and applications. African J. Pharm. Pharmacol. 7 (17), 873–881.
Ali, J., Bhatnagar, A., Kumar, N., Ali, A., 2014. Chitosan nanoparticles amplify the ocular hypotensive effect of catechol in rabbits. Int. J. Biol. Macromol. 65, 479–491.
Ammar, H., El-Nahhas, S., Khalil, R., 1998. Cycloexdrin in acetazolamide eye drop formulations. Die Pharmazie 53 (8), 559–562.
Ammar, H.O., Salama, H., Ghorab, M., Mahmoud, A., 2009. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm. Sci. Tech. 10 (3), 808.
Amruta, N., Bajaj, A., Madaan, M., 2009. Development of microsponges for topical delivery of murpiron. AAPS Pharm. Sci. Tech. 10 (2), 402–409.
Asasutjarit, R., Thanasanchokpitull, S., Fuongchhat, A., Veeranondha, S., 2011. Optimization and evaluation of thermo-responsive diloefon sodium ophthalmic in situ gels. Int. J. Pharmaceut. 411 (1), 128–135.
Baeyens, V., Felt-Baeyens, O., Rougier, S., Pheluin, J., Boisrame, B., Gurny, R., 2002. Clinical evaluation of bioadhesive ophthalmic drug inserts (BDI®) for the treatment of external ocular infections in dogs. J. Controlled Release 85 (1), 163–168.
Camargo, E.E., 2001. Brain SPECT in neurology and psychiatry. J. Nucl. Med. 42 (4), 611–623.
Çomölü, T., Gönül, N., Baykara, T., 2003. Preparation and in vitro evaluation of modified release ketoprofen microsponges. Il Farmaco 58 (2), 101–106.
Costa, P., Lobo, J.M.S., 2001. Modeling and comparison of dissolution profiles. Eur. J. Pharmaceut. Sci. 13 (2), 123–133.
El-Gazawy, O.N., Hikai, A.H., 1997. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int. J. Pharmaceut. 158 (2), 121–127.
El-Laithy, H., Neeseem, D., Shoukry, M., 2011. Evaluation of two in situ gelling systems for ocular delivery of Moxifloxacin: in vitro and in vivo studies. J. Chem. Pharmaceut. Res. 3 (2), 66–79.
Epstein, D.L., Grant, W.M., 1977. Carbonic anhydrase inhibitor side effects: serum chemical analysis. Arch. Ophthalmol. 95 (8), 1378–1382.
Fialho, S.L., Silva-Cunha, D., 2004. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin. Exp. Ophthalmol. 32 (6), 626–632.
Fiscella, R.G., 2008. Chapter 2 - Ophthalmic Drug Formulations. Clinical Ocular Pharmacology (Fifth Edition). Butterworth-Heinemann, Saint Louis, pp. 17–37.
Friedman, Z., Allen, R.C., Raph, S.M., 1985. Topical acetazolamide and methazolamide delivered by contact lenses. Arch. Ophthalmol. 103 (7), 963–966.
Granero, G., Longhi, M., Becker, C., Junghering, H., Kopp, S., Midha, K., Shah, V., Stavchansky, S., Dressman, J., Barends, D., 2008. Bioanalyser monographs for immediate release solid oral dosage forms: Acetazolamide. J. Pharmaceut. Sci. 97 (9), 3691–3699.
Guinedi, A.S., Mortada, N.D., Mansour, S., Hathour, M.R., 2005. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int. J. Pharmaceut. 306 (1), 71–82.
Hathour, M.R., Mansour, S., Mortada, N.D., Guinedi, A.S., 2007. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharm. Sci. Tech. 8 (1), E1–E12.
Igeo, S., 2012. A guide to dynamic light scattering measurement and analysis. NanoComposix.
Jadhav, N., Patil, V., Munegak, S., Bhambare, G., Karpe, M., Kadam, V., 2013. Microsphere delivery system: an updated review, current status and future prospects. J. Sci. Innov. Res. 2 (6), 1097–1110.
Jain, V., Singh, R., 2011. Design and characterization of colon-specific drug delivery system containing paracetamol microspheres. Arch. Pharm. Res. 34 (5), 733–740.
Jelvehgari, M., Siahi-Shadlab, M.R., Azarmi, S., Martin, G.P., Nokhodchi, A., 2006. The microsphere delivery system of benzoyl peroxide: preparation, characterization and release studies. Int. J. Pharmaceut. 308 (1–2), 124–132.
Kaur, I.P., Singh, M., Kanwar, M., 2000. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int. J. Pharmaceut. 199 (2), 119–127.
Krauland, A.H., Leitner, V.M., Bernkop-Schnürch, A., 2003. Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of thiol groups. J. Pharmaceut. Sci. 92 (6), 1234–1241.
Lallemand, F., Furrer, P., Felt-Baeyens, O., Gex-Fabry, M., Dumont, J.-M., Besseggar, B., Gurny, R., 2005. A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics. Int. J. Pharmaceut. Sci. 295 (1), 7–14.
Marques, M.R., Loebenberg, R., Almukainzi, M., 2011. Simulated biological fluids with possible application in dissolution testing. Dissolution Technol. 18 (3), 15–28.
Mishra, V., Jain, N.K., 2014b. Acetazolamide encapsulated dendritic nanoarchitectures for effective glaucoma management in rabbits. Int. J. Pharmaceut. 461 (1–2), 380–390.
Mishra, V., Jain, N., 2014a. Acetazolamide encapsulated dendritic nanoarchitectures for effective glaucoma management in rabbits. Int. J. Pharmaceut. 461 (1), 380–390.
Monem, A.S., Ali, F.M., Issmail, M.W., 2000. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int. J. Pharmaceut. 198 (1), 29–38.
Mora, M.J., Tartara, L.L., Onnainiy, R., Palma, S.D., Longhi, M.R., Granero, G.E., 2013. Characterization, dissolution and in vivo evaluation of solid acetazolamide complexes. Carbohydrate Polym. 98 (1), 380–389.
Morsi, N., Mohamed, M., Refai, H., El Sorogy, H., 2014. Nanoemulsion as a novel ophthalmic delivery system for acetazolamide. Int. J. Pharmaceut. Sci. 6 (11), 227–236.
Morsi, N., Ghorab, D., Refai, H., Teba, H., 2016. Ketorolac tromethamine loaded nanodispersion incorporated into thermostensitive in situ gel for prolonged ocular delivery. Int. J. Pharmaceut. 506 (1–2), 57–67.
Morsi, N., Ibrahim, M., Refai, H., El Sorogy, H., 2017. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur. J. Pharmaceut. Sci. 104, 302–314.

Nokhodchi, A., Jelvæghari, M., Siah, M.-R., Dastmalchi, S., 2005. The effect of formulation type on the release of benzoyl peroxide from microsponges. Iranian J. Pharmaceut. Sci. 1 (3), 131–142.

Parikh, B., 2010. Microspoonge as novel topical drug delivery system. J. Global Pharma Technol. 2 (1).

Qi, H., Chen, W., Huang, C., Li, L., Chen, C., Li, W., Wu, C., 2007. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharmaceut. 337 (1), 178–187.

Rajasekaran, A., Kumaran, K., Preetha, J.P., Karthika, K., 2010. A comparative review on conventional and advanced ocular drug delivery formulations. Int. J. Pharm. Tech. Res. 2 (1), 668–674.

Rathore, K., Nema, R., 2009. An insight into ophthalmic drug delivery system. Int. J. Pharm. Sci. Drug Res. 1 (1), 1–5.

Re, M., Biscans, B., 1999. Preparation of microspheres of ketoprofen with acrylic polymers by a quasi-emulsion solvent diffusion method. Powder Technol. 101 (2), 120–133.

Robinson, J.R., Mlynek, G.M., 1995. Bioadhesive and phase-change polymers for ocular drug delivery. Adv. Drug Deliv. Rev. 16 (1), 45–50.

Saifullah, M., Ahsan, A., Shishir, M.R.I., 2016. Production, stability and application of micro- and nanoemulsion in food production and the food processing industry A2 - Grumezescu, Alexandru Mihai Emulsions. Acad. Press, 405–442.

Schmolka, I.R., 1972. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. Part A 6 (6), 571–582.

Song, J., Bi, H., Xie, X., Guo, J., Wang, X., Liu, D., 2013. Preparation and evaluation of simonenine hydrochloride in situ gel for uveitis treatment. Int. Immunopharmacol. 17 (1), 99–107.

Srivastava, R., Pathak, K., 2012. Microsponges: a futuristic approach for oral drug delivery. Expert Opin. Drug Deliv. 9 (7), 863–878.

Tangri, P., Khurana, S., 2011. Basics of ocular drug delivery systems. Int. J. Res. Pharmaceut. Biomed. Sci. 2 (4), 1541–1552.

Varshosaz, J., Tabbakhian, M., Salmani, Z., 2008. Designing of a thermosensitive chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin. Open Drug Deliv. J. 2 (1).

Venkatesh, M., Purohit, K., Kumar, P., 2013. Development and evaluation of chitosan based thermosensitive in situ gels of pilocarpine. Int. J. Pharm. Pharm. Sci. 1 (5), 164–169.

Vyas, L., Tapar, K., Laddha, B., Lahoti, A., Nema, R., 2010. Formulation and development of anti-blemish preparations using microspone technology. J. Chem. Pharm. Res. 2 (5), 562–571.

Vyslouzil, J., Dolezel, P., Kejdušová, M., Mašková, E., Mašek, J., Lukáč, R., Košíál, V., Vetchý, D., Dvořáčková, K., 2014. Influence of different formulations and process parameters during the preparation of drug-loaded PLGA microspheres evaluated by multivariate data analysis. Acta Pharmaceutica 64 (4), 403–417.

Yang, Y.-Y., Chung, T.-S., Ng, N.P., 2001. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22 (3), 231–241.